Skip to main content

Table 1 Summary of patients’ clinical and demographic data

From: An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration

ID

Sex

Age

Diagnosis

Infective diagnosis

APACHE II Score1

CrCl2

Duration CVVHDF (days)

P1

M

57

Cirrhosis of liver, sepsis, ARF

Pseudomonas aeruginosa

39

10

7

P2

F

68

Colonic obstruction, post-op ARF, sepsis

Pseudomonas aeruginosa

28

8

14

P3

M

59

ALL with neutropenic sepsis and ARF

Empiric cover for sepsis

24

5

10

P4

M

63

Ruptured abdominal aortic aneurysm repair with post-op ARF and sepsis

Acinetobacter baumanni

18

5

13

P5

F

70

Pneumonia, ARDS

Klebsiella pneumoniae

24

2

11

Mean

 

63.4

 

-

26.6

6

11

  1. 1 Initial/ICU admission value.
  2. 2 Creatinine clearance value on day 1 of CVVHDF, prior to commencing CVVHDF therapy. Units = ml/min; estimated using the method of Jelliffe and Jelliffe.
  3. ARF = Acute renal failure.
  4. ALL = Acute lymphocytic leukaemia.
  5. ARDS = Acute Respiratory Distress Syndrome.